Taken together, these results demonstrate that gut microbiota varies with mouse strain, antibiotic treatment, and oral transfer of bacteria, as well as that gut microbiota modulation affects the tumour-suppressive efficacy of Tim-3 blockade. This evidence concerns the gene HAVCR2 and neoplasm.